Clinical Trial

A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study will be conducted to evaluate the safety, efficacy, and pharmacokinetics of axatilimab monotherapy in Chinese participants with recurrent or refractory active chronic graft-versus-host disease after systemic therapy.
Protocol Amendment History 3 changes
critical Enrollment closed, study ongoing 2026-08-11
notable Primary completion pushed: 2026-07-03 -> 2027-01-06 2026-08-11
minor Completion pushed: 2027-12-31 -> 2028-07-20 2026-08-11
Trial Details
NCT Number NCT06843408
Lead Sponsor Incyte Corporation
Conditions Chronic Graft-versus-host-disease
Enrollment 32 participants
Start Date 2025-06-25
Primary Completion 2027-01-06 (estimated)
Study Completion 2028-07-20 (estimated)
Updated on ClinicalTrials.gov 2026-08-10